ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Lung Cancer

Lung Cancer

Two parts of a phase I trial found that nivolumab could be a good first-line treatment option for patients with advanced non–small-cell lung cancer.

The FGFR inhibitor dovitinib showed modest efficacy in a phase II trial of patients with pretreated, advanced squamous cell lung cancer with FGFR1 amplification

The use of hemithoracic pleural IMRT after chemotherapy could become part of a new lung-sparing therapy in patients with malignant pleural mesothelioma.

Alectinib yielded significantly prolonged progression-free survival compared with crizotinib in ALK-positive NSCLC patients, according to results of a Japanese open-label trial.

An antibody-drug conjugate, rovalpituzumab tesirine, shows promising efficacy against recurrent small-cell lung cancer.

Matching targeted therapies to genetic abnormalities harbored by tumor types for which those therapies are not approved by the FDA might expand treatment options for some patients with advanced cancers.

The UK Lung Cancer Screening Trial found that a low-dose CT screening program targeting high-risk individuals can find lung cancer at early stages.

Pages

Subscribe to Lung Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.